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An integrated care intervention including education, coordination among levels of care,
and improved accessibility, reduced hospital readmissions in chronic obstructive
pulmonary disease (COPD) after 1 year. This study analyses the effectiveness of this
intervention in terms of clinical and functional status, quality of life, lifestyle, and self-
management, under the hypothesis that changes in these factors could explain the
observed reduction in readmissions.
A total of 113 exacerbated COPD patients (14% female, mean (SD) age 73(8) years, FEV1
1.2(0.5) l) were recruited after hospital discharge in Barcelona, Spain, and randomly
assigned (1:2) to integrated care (IC) (n ¼ 44) or usual care (UC) (n ¼ 69). The intervention
consisted of an individually tailored care plan at discharge shared with the primary care
team and access to a specialized case manager nurse through a web-based call centre.
After 1 year of intervention, subjects in the intervention group improved body mass index
by 1.34 kg/m2. Additionally, they scored better in self-management items: COPD
knowledge 81% vs. 44%, exacerbation identification 85% vs. 22%, exacerbation early
treatment 90% vs. 66%, inhaler adherence 71 vs. 37%, and inhaler correctness 86 vs. 24%.
There were no differences in the evolution of dyspnea, lung function, quality of life scores,
lifestyle factors, or medical treatment.
Conclusions: This IC trial improved disease knowledge, and treatment adherence, after 1
year of intervention, suggesting that these factors may play a role in the prevention of
severe COPD exacerbations triggering hospital admissions.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
3160590; fax: +34 93 3160635.
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The burden of chronic obstructive pulmonary disease (COPD)
is very high in terms of prevalence, morbidity, mortality and
economic costs.1 The need to reduce this burden, in the
context of a general concern about chronic diseases
management,2 has prompted the development of new
management strategies for COPD. These strategies focus
particularly on the active role of the individual3 (self-
management programmes), with the aim of avoiding the
rigidity and fragmentation of traditional healthcare sys-
tems.4,5 The intervention relies on care arrangements
being shared between professionals working in different
levels of the healthcare system and promotes accessi-
bility of target patients to healthcare professionals follow-
ing well-standardized procedures.6 Knowledge about effec-
tiveness and cost of these new approaches in COPD is still
scarce.
Self-management education programmes try to teach
patients how to carry out the activities of daily living
optimally, and to prevent or decrease the severity of
exacerbations by early recognition and treatment of the
episodes.7 A self-management programme in COPD patients
in Quebec reduced hospital admissions and emergency-room
visits during the 1 year study period.8 Patients maintained a
significant reduction in hospitalization risk after a 2-year
period.9 However, most of the educational programmes
have found negative or inconclusive results with regard
to health services use, lung function, respiratory symp-
toms or health-related quality of life.7 An innovative
management strategy is hospital at home or supported
discharge, which are proposed as an alternative to hospital
admission when a COPD exacerbation appears, to increase
patients’ satisfaction and reduce costs, without adverse
health effects for the patients.10 Compared to inpatient
treatment, hospital at home or supported discharge
programmes reduce costs, free up hospital inpatient beds,
and are safe for the patients, but do not change risk of
hospital readmission or mortality.10 Recently, systematic
reviews of educational and home hospitalization pro-
grammes have revealed that differences in populations
under study, in content of the programmes, and in outcome
measures, make the generalization of their results difficult,
implying that more research is needed in this area before
recommending these treatments.7,10
In a recent paper, we reported that an integrated care
intervention including education, coordination among levels
of care, and improved accessibility, reduced hospital read-
missions in COPD after 1 year of follow-up by 50%, in a
randomized controlled trial in 155 COPD patients from
Barcelona, Spain, and Leuven, Belgium, both in the pooled
and by-site analysis.6 The present analysis in the subgroup of
patients from Barcelona, aims to assess the effectiveness of
this intervention in terms of enhancing clinical status
(dyspnea, body mass index (BMI)), health-related quality
of life, lifestyle (smoking, physical activity), self-manage-
ment (COPD knowledge, alarm knowledge and treatment,
treatment adherence), medical treatment, and patients’
satisfaction, after a 1-year follow-up period, under the
hypothesis that changes in these factors could explain the
reduction in readmissions. Functional status (lung function
and arterial blood gases) was also measured.Methods
Design
Randomized controlled trial, subjects were assessed at
baseline. The follow-up period was prolonged for one full
year with patient’s assessment performed at 6 and 12
months.
Subjects
A total of 113 COPD patients were consecutively recruited
during 1 year in one tertiary hospital (Hospital Clı´nic) in
Barcelona, Spain, immediately after hospital discharge, and
were blindly assigned (1:2 ratio) using computer generated
random numbers either to integrated care (IC) or to usual
care (UC). All of them had been admitted because of an
episode of exacerbation requiring hospitalization for more
than 48 h. Exclusion criteria for the study were: (1) not living
in the healthcare area or living in a nursing home; (2) lung
cancer or other advanced malignancies; (3) logistic limita-
tions due to extremely poor social conditions, illiteracy, or
no phone access at home; and (4) extremely severe
neurological or cardiovascular co-morbidities. All partici-
pants were informed in detail of the characteristics of the
study, and written informed consent was obtained in
accordance with the Committee on Investigations Involving
Human Subjects at the hospital.
Integrated care (IC) intervention
The IC intervention has been described in detail elsewhere6
and includes 4 key features. First, a comprehensive
assessment of the patient at discharge including severity
of the respiratory disease, evaluation of co-morbid condi-
tions, treatment adherence, and analysis of requirements in
terms of social support, was done by a specialized nurse.
Secondly, an educational session of approximately 2 h
duration on self-management of the disease was adminis-
tered at discharge, also by the specialized respiratory nurse
specifically trained for the study intervention. This session
covered several items, including knowledge of the disease,
smoking cessation, promotion of physical activity, nutrition
recommendations and other instructions on non-pharmaco-
logical treatment, assessment of correctness of administra-
tion techniques for pharmacological therapy and teaching
of self-management strategies to cope with future exacer-
bations.11,12 Written information was provided to all pa-
tients.13 Education on skills to identify clinical deterioration
was an important aspect of the programme. Patients were
taught to generate a phone call to the call centre if
symptoms or signs indicating clinical deterioration occurred.
The call was transferred to a specialized nurse (case
manager) that either solved the problem by phone or
triggered a home visit. Thirdly, an individually tailored care
plan, following international guidelines,12,14 was elaborated
through the interaction between the specialized nurse case
manager and the primary care team. Reinforcement of the
logistics for treatment of co-morbidities and social support
was done accordingly. One joint visit of the specialized nurse
and the primary care team (physician, nurse and social
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discharge. Weekly phone calls during the first month after
discharge and one phone call at months 3 and 9 were carried
out to reinforce self-management strategies. Lastly, access
to the specialized nurse at the hospital was guaranteed to
patients, caregivers and primary care professionals during
the follow-up period through an Information and Commu-
nication Technologies (ICT) platform including a web-based
call centre.15 It is important to note that the IC intervention
did not include further scheduled visits during the follow-up
period. Non-scheduled visits could be triggered by the
patients through the call centre.
Usual care (UC) group
Patients included in the UC group were discharged from the
hospital by the attending physician who decided on the
outpatient control regime. Pharmacological prescriptions at
discharge and in-hospital treatment followed the standard
protocols of the centre and were similar in the two groups
(IC and UC).12,14 However, patients did not receive the
support of a specialized nurse which included the educa-
tional session, joint visit with the primary care team, nor
was access to the call-centre provided.
Variables and instruments
Early assessment of patients at their admission to the study
was identical for both groups. It included a blind adminis-
tration of a questionnaire, described in detail elsewhere11,16
concerning: sociodemographic factors (sex, age, educa-
tional level, economic status and caregiver support); clinical
factors (co-morbidities, dyspnea (Medical Research Council
scale), body mass index (BMI), and previous hospital and
emergency room admissions due to COPD); health-related
quality of life (Saint-George’s Respiratory Questionnaire
(SGRQ) and Euroqol (EQ-5D)); lifestyle (smoking, alcohol,
and physical activity); self-management (knowledge about
symptoms and treatment of COPD, identification and early
treatment of a COPD exacerbation, treatment adherence—us-
ing the Medication Adherence Scale (MAS) and Inhaler
Adherence Scale (IAS),17 and observed skills for administration
of inhaled drugs18); drug (short and long-acting b2-agonists,
anticholinergics, methilxanthines, inhaled and oral corticos-
teroids) and non-drug treatment (vaccines, oxygen therapy);
and satisfaction with health services. Vital signs, chest X-ray
films, and pulmonary function tests, including arterial blood
gases, were obtained in all patients on admission.
At 6 and 12 months of follow-up, the same questionnaires
and lung function tests were administered to the two arms
of the study together with a detailed list of questions on the
utilization of healthcare resources during each period.
Statistical analysis
Results are expressed as mean (SD), median (P25–P75), or as
number (percentage) in the corresponding categories. To
assess the possibility of selection bias, comparisons of
baseline characteristics between UC and IC, both for the
followed-up and for the lost subjects were performed using
independent t-tests, Kruskal–Wallis test or the Chi-squaretest, depending on the distribution of each variable. Since
data about outcome variables was not available in the lost
subjects (whether due to exclusion, loss to follow-up or
death), an intention-to-treat principle was not possible.
Thus, all analyses about the impact of intervention were
restricted to subjects with complete data during the follow-
up. No values were imputed to subjects lost to follow-up.
Four approaches were used. First, for continuous variables,
the difference between 12 months values and baseline
values was modelled using linear regression. Second, for
categorical variables, the difference between 12 months
and baseline values was turned into three categories (no
change, improvement, or impairment), which were mod-
elled using politomic logistic regression. Since many of the
variables had a very small number of subjects in some
categories, the politomic logistic regression led to large
confidence intervals. Therefore, and considering that there
were no baseline differences in these categorical variables
between the UC and IC groups, final (12 months) values were
directly compared between groups using chi-square test,
and these are the results which are actually shown. Finally,
variance analysis with repeated events, which allowed to
include 6 months values and a better modelling of changes
over time, was also used for all outcome variables. This
analysis provided both differences among groups (p-group
effect) and differences among periods (p-time effect). No
adjustment for baseline variables was done in any of the
approaches, since there were no baseline differences
between groups.Results
Fig. 1 displays patient’s flow throughout the study. One
hundred and thirteen subjects were identified and randomly
assigned to the intervention or control group. Five subjects
refused to participate. During follow-up, a priori defined
exclusion criteria, such as lung cancer, appeared in 9 subjects.
Twenty-one subjects died, and 16 were lost to follow-up. Only
57% of subjects finished the study at 12 months.
Subjects were mostly male, over 70 years old, and suffered
from severe COPD. Table 1 shows baseline characteristics of
the subjects, comparing the UC and IC groups, according to
whether subjects were lost or completed the follow-up. No
differences were found at baseline between the UC and IC
groups, except for the SGRQ score, which was lower in the IC
group than the UC group among those that completed the
follow-up, this difference being clinically important although
not statistically significant. No differences in adherence, drug
and non-drug treatments were found (not shown). Subjects
who were lost for the present analysis had a higher number of
COPD admissions in the previous year and in the follow-up
year, and they were using long-term oxygen therapy in a higher
proportion than those subjects who participated in the 12
months assessment.
Table 2 shows changes (difference between 12 months
and baseline) in clinical, functional and quality of life
variables, by groups of treatment, as well as the difference
of this change in the IC group compared to the UC group,
which is equal to the coefficient of the linear regression
model. Dyspnea worsened slightly in both groups during the
follow-up period. Body mass index did not change in the UC
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Figure 1 Flow chart of patients participation in the study.
Integrated care in COPD 1465group while it increased in the IC group, this difference
being statistically significant. Lung function did not change
in any group. Arterial oxygenation improved in both groups,
without statistically significant differences between groups.
Quality of life scores (according to the SGRQ and the Euroqol
visual analogue scale) slightly improved in the follow-up
year, without differences between groups, with the excep-
tion of the symptoms score, which improved more in the IC
group, this difference not being statistically significant.
There were no differences in smoking habits or physical
activity practice at 12 months between the UC and IC groups
(Table 3). All variables related to self-management (COPD
knowledge, identification and treatment of a COPD exacer-
bation, and adherence to treatment), were better in the IC
group than in the UC group, most of these differences being
statistically significant. There were no differences in
pharmacological or non-pharmacological treatments, or
degree of satisfaction of the patients between groups.
Variance analysis with repeated events, which allowed
inclusion of 6 months values, was performed for all
variables. With the exception of PaO2, no additional
information was obtained from this analysis, since most
variables followed the same pattern in the various intervals
(baseline—6 months, 6–12 months, baseline—12m). How-
ever, PaO2 improved between baseline and 6 months in both
groups, and afterwards improved further in the IC group
while it worsened in the UC group (Fig. 2).Discussion
This is one of the few studies that have examined and
showed that IC, including self-management education,coordination among levels of care, and increased accessi-
bility in COPD patients, is associated with an improvement
in disease knowledge, treatment adherence and nutritional
status. The study was not able to show changes in lifestyle
variables, medical treatment, lung function or quality of
life. A complete interpretation of these results needs to
consider that this intervention was effective to reduce COPD
admission risk.6
The intervention improved disease knowledge, consis-
tently with previous trials of self-management,19 home
based care,20 or respiratory rehabilitation21), which in-
cluded education as a component. The importance of the
present findings lies in three key issues: (i) the present
programme was not intensive in education, including only a
session of 2 h at baseline supported by the practice team;
(ii) effects persisted after 12 months, while previous
studies, with more intensive interventions, reported effects
after shorter periods of follow-up19,20; (iii) we also assessed
the effect of intervention on hospital admissions, which
allows us to hypothesize that the increase in knowledge
could be partially responsible for the previously reported
reduction in admissions.6 It is likely that, even without
changes in the frequency or severity of COPD exacerbations,
subjects with better knowledge and skills may not need
hospital admission because of an early treatment of the
exacerbation. This is supported by a previous study in a
panel of COPD patients which found that early treatment of
COPD exacerbation improved exacerbation recovery and
reduced risk of hospitalization22).
Self-reported adherence to inhaled medication and
performance of the inhaler manoeuvre improved in the IC
group, according to a previous educational programme
which found an improvement in the inhalation technique
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Table 1 Subjects’ characteristics in usual care (UC) and integrated care (IC) groups, according to follow-up status.
Lost to follow-up (death, lost or excluded) Followed-up P (lost vs.
followed)
Usual care (UC) Integrated care
(IC)
P Usual care (UC) Integrated care
(IC)
P
n ¼ 28 n ¼ 23 n ¼ 41 n ¼ 21
Sex: female n (%) 1 (4) 7 (30) 0.009 4 (10) 4 (20) 0.302 0.673
Age (years) m (SD) 74 (8) 73 (6) 0.717 73 (9) 72 (10) 0.829 0.675
Less than primary education n (%) 5 (19) 8 (36) 0.159 13 (33) 5 (24) 0.480 0.730
Smoking
Current n (%) 3 (11) 4 (17) 0.571 6 (15) 5 (24) 0.571 0.819
Former n (%) 23 (82) 16 (70) 31 (76) 15 (71)
Never n (%) 2 (7) 3 (13) 4 (10) 1 (5)
Dyspnea (MRC scale) Median (P25–P75) 4 (3–5) 5 (3–5) 0.197 4 (3–5) 3 (3–4) 0.601 0.390
BMI (kg/m2) m (SD) 25.6 (5.9) 26.3 (5.9) 0.700 27.4 (5.7) 28.1 (4.3) 0.632 0.117
FEV1 (l) Median (P25–P75) 1.1 (0.8–1.5) 1.0 (0.8–1.5) 0.550 1.0 (0.8–1.5) 1.2 (0.8–1.4) 0.512 0.929
FEV1/FVC (%) m (SD) 54 (18) 57 (18) 0.524 51 (18) 48 (17) 0.613 0.126
PaO2 (mmHg) m (SD) 65 (14) 62 (14) 0.399 61 (9) 64 (10) 0.323 0.446
PaCO2 (mmHg) m (SD) 43.3 (9.1) 44.1 (8.4) 0.750 43.8 (6.5) 43.1 (6.6) 0.715 0.916
Any comorbidity n (%) 27 (96) 19 (83) 0.099 39 (93) 17 (81) 0.167 0.799
COPD admissions in the last year Median
(P25–P75)
0 (0–1) 1 (1–2) 0.004 0 (0–1) 0 (0–1) 0.929 0.003
COPD admissions during follow-up Median
(P25–P75)
1 (0–2) 1 (0–2) 0.813 1 (0–1) 0 (0–1) 0.083 0.077
Long-term oxygen therapy n (%) 11 (39) 9 (39) 0.991 8 (20) 6 (29) 0.419 0.055
Health-related quality of life (SGRQ) m (SD) 53.4 (19.3) 61.8 (17.6) 0.131 60.5 (20.2) 51.2 (16.9) 0.077 0.951
Saint-George’s Respiratory Questionnaire (SGRQ) score goes from 0 (better health status) to100 (worse health status). J.
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Table 3 Lifestyle factors, self-management, medical treatment, and health care satisfaction, at 12 months, in UC and IC
groups.
Usual care (UC) Integrated care (IC)
n ¼ 41 n ¼ 21 P
No current smokers n (%) 36 (88) 20 (95) 0.349
Any physical activity n (%) 34 (83) 18 (86) 0.778
Regular walking or exercising n (%) 32 (78) 18 (86) 0.470
Knowledge about
Name of the disease (COPD) n (%) 18 (44) 17 (81) 0.005
Identification of a COPD exacerbation n (%) 9 (22) 17 (85) o0.001
Early treatment of a COPD exacerbation n (%) 27 (66) 19 (90) 0.036
Adherence to oral treatment (MAS scale) n (%) 35 (85) 19 (90) 0.570
Adherence to inhaled treatment (IAS scale)* n (%) 15 (37) 15 (71) 0.009
Correct inhaler manoeuvre n (%) 9 (24) 18 (86) o0.001
Long-term oxygen therapy X16 h n (%) n ¼ 23 15 (94) 7 (100) 0.499
Influenza vaccination n (%) 32 (78) 19 (90) 0.442
Pneumococcal vaccination n (%) 25 (61) 16 (76) 0.348
Long-term oxygen therapy n (%) n (%) 16 (39) 7 (33) 0.661
Short-acting b2-agonists n (%) 36 (88) 21 (100) 0.095
Long-acting b2-agonists n (%) 31 (76) 11 (52) 0.064
Anticholinergics n (%) 32 (78) 15 (71) 0.565
Methilxanthines n (%) 1 (2) 0 (0) 0.471
Inhaled corticosteroids n (%) 30 (73) 19 (90) 0.113
Oral corticosteroids n (%) 1 (2) 2 (10) 0.219
Satisfaction with health care n (%) 34 (92) 21 (100) 0.180
MAS and IAS continuous scores were recoded as compliant (all correct answers in the scale), and non-compliant (one or more
mistakes).
Table 2 Changes in clinical status, functional status, and quality of life between baseline and 12 months, in UC and IC groups
(linear regression).
Change, m (SD) (12
months—baseline values)
Linear regression
Usual care (UC) Integrated care
(IC)
coefficient (95% CI) P
n ¼ 41 n ¼ 21
Dyspnea score (MRC) 0.15 (1.44) 0.52 (1.12) 0.38 (1.1 to 0.34) 0.299
BMI (kg/m2) 0.01 (1.63) 1.33 (1.73) 1.34 (0.31 to 2.37) 0.012
FEV1 (l) 0.06 (0.35) 0.01 (0.14) 0.05 (0.24 to 0.14) 0.569
FEV1/FVC (%) 1.66 (17.94) 0.82 (8.18) 0.84 (8.27 to 10.66) 0.863
PaO2 (mmHg) 3.12 (8.5) 5.36 (8.54) 2.24 (2.57 to 7.06) 0.355
PaCO2 (mmHg) 1.1 (5.57) 0.26 (5.24) 0.84 (2.25 to 3.93) 0.588
Specific health-related quality of life (SGRQy)
Symptoms 17.11 (24.44) 24.4 (19.68) 7.29 (19.66 to 5.07) 0.243
Activity 8.36 (19.95) 5.08 (16.61) 3.27 (6.91 to 13.46) 0.523
Impact 11.29 (16.34) 13.7 (15.62) 2.41 (11.24 to 6.42) 0.587
Total 11.02 (15.57) 13.41 (13.43) 2.39 (10.56 to 5.78) 0.560
Generic health-related quality of life (Euroqolz) 0.93 (2.11) 1.56 (1.77) 0.62 (0.51 to 1.75) 0.273
Relative change in IC group compared to UC group.
ySRGQ score goes from 0 (better health status) to100 (worse health status). Negative change means improvement.
zEuroqol score goes from 0 (worse health status) to 10 (better health status). Positive change means improvement.
Integrated care in COPD 1467
ARTICLE IN PRESS
PaO2
71.368.6
65.6
64.9
68.5
61.4
55
60
65
70
75
80
baseline 6 months 12 months
M
e
a
n
 (
m
m
H
g
)
IC UC
p group effect 0.051
p time effect <0.001
Figure 2 Changes in mean PaO2 values (mmHg) along time, in
UC (n ¼ 41) and IC (n ¼ 21) groups.
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treatment in COPD are not known, and it has been said that
studies using adherence as an outcome should also measure
clinical benefits.24 Although we cannot attribute the
reduction of the admissions risk6 to any specific component
or effect of the intervention, our data suggest that
treatment adherence may have positive effects in COPD
patients.
Nutritional status (as measured with body mass index) did
not change in the UC group while it increased steadily in the
IC group. We are not aware of any educational trial that
measured nutritional status in COPD patients. Since there
were no undernourished patients (only 1 patient had
BMIp20), nutritional advice of our intervention was
directed to avoid overweight. The difference at 12 months,
although small in absolute numbers (1.34 kg/m2), could be
due to the higher rate of admissions during the follow-up
period in the UC group, which would have had a negative
effect on nutritional status. One limitation of the study was
the lack of measurement of fat free mass index.
The lack of change in lung function after 1 year of
intervention is consistent with previous findings of educa-
tional7,8 or home based care25–27 programmes, and plausible
given the natural history of COPD.28 However, we found that
pulmonary gas exchange improved in both groups until 6
months, something probably due to recovery after the
exacerbation, and, from 6 to 12 months, worsened in the UC
group while it improved in the IC group. One likely
explanation is that the intervention leads to a better control
of hypoxemia. However, the lack of differences in oxygen
prescription and oxygen compliance between groups of
treatment may rule out this possibility. Another explanation
could be that changes in the course of the disease during the
12 months of treatment (such as exacerbations and
admissions) are responsible for final values of pulmonary
gases exchange. Existing literature does not help in under-
standing these findings, since none of the previous studies
measured arterial blood gases, and only one study involving
supported discharge intervention26 found that oxygen
saturation improved at 8 weeks in the treated group without
changes in the control group.
We did not find differences in general (Euroqol) or specific
(SGRQ) health-related quality of life (HRQL) measures,
although both improved in both groups as a result of
recovery after the exacerbation.29 A meta-analysis of
educational programmes in COPD did not find effects inthe general HRQL, and only small effects in the specific
HRQL measures.7 Most of the home care or supported
discharge programmes assessed their effect in specific
HRQL, and only one found improvements after a short
period of time,11 while the remainder did not find effects
after short,26 medium,27 or long periods.25 Since trials of
respiratory rehabilitation, which share some of the compo-
nents with educational or home care based interventions,
found an effect in quality of life,21 it could be hypothesized
that this effect is not attributable to ‘‘education’’ but to
other components, among which ‘‘exercise’’ would be a key
candidate, given the strong association between quality of
life and physical activity in COPD patients.30 In fact, a study
which included self-management and exercise training
without supervision in COPD8 found improvements in the
impact subscale of the SGRQ at 4 months but not at 12
months, their difference between groups being lower than
what we found in symptoms.
The lack of differences in pharmacological prescriptions
between UC and IC groups suggests that adherence to
international guidelines in severe COPD after a hospital
admission, is acceptable in our area. In addition, treatment
of co-morbidities at 12 months was scored as correct in 100%
of patients both in the UC and IC group. We did not find
changes in smoking or physical activity habits related to the
intervention, probably because of a ceiling effect.
Main limitations of the present study are the small sample
size and the high proportion of patients lost to follow-up.
The study sample size was computed to answer the primary
objective of reduction in admissions in all subjects included
in the trial, but unfortunately only part of the patients
(those from Barcelona) had information about changes in
risk factors. Even then, sample size was very similar to
previous educational or home care intervention studies. We
tested the degree of selection bias by comparing character-
istics of subjects lost to follow-up between the IC and UC
groups. There was no relationship between variables that
were different in these groups and outcome variables,
reducing the possibility of selection bias as an explanation
for the present results (data available from the authors).
The extent to which our intervention can be exported to
other subgroups of the COPD population or other health care
systems is debatable and has been discussed elsewhere.6 We
conclude that, compared to UC, an IC programme including
education, coordination among levels of care and increased
accessibility, helped COPD patients to enhance knowledge
and to influence health behaviour such as treatment
adherence after 1 year of intervention. The interpretation
of these findings together with the previously reported
reduction in admission risk, suggest that these factors play
an important role in the treatment of COPD exacerbations at
an early stage, being able to reduce the need of hospital
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